Case Report

Published on 29 Aug 2024

A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review

in Pharmacology of Anti-Cancer Drugs

Xiaqin Cheng
Jia Liu
Qiongxia Hu
Yingchun Gao
Lin Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1430350

647 views

Retraction

Published on 27 Aug 2024

Retraction: Disulfiram chelated with copper inhibits the growth of gastric cancer cells by modulating stress response and Wnt/β-catenin signaling

in Pharmacology of Anti-Cancer Drugs

Frontiers in Oncology

doi 10.3389/fonc.2024.1475033

537 views

Editorial

Published on 26 Aug 2024

Editorial: Immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects

in Pharmacology of Anti-Cancer Drugs

Aysin Tulunay Virlan
Giacomo Cafaro
Flavia Sunzini
Yannick Degboe
Maria-Ioanna Christodoulou

Frontiers in Oncology

doi 10.3389/fonc.2024.1476475

652 views

Review

Published on 16 Jul 2024

Progress of natural sesquiterpenoids in the treatment of hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Xiaodong Wang
Fancheng Meng
Jingxin Mao

Frontiers in Oncology

doi 10.3389/fonc.2024.1445222

1,232 views

Brief Research Report

Published on 15 Jul 2024

Withametelin inhibits TGF-β induced Epithelial-to-Mesenchymal Transition and Programmed-Death Ligand-1 expression in vitro

in Pharmacology of Anti-Cancer Drugs

Ashna Fathima
Mohammad Ali Farboodniay Jahromi
Sajeli A. Begum
Trinath Jamma

Frontiers in Oncology

doi 10.3389/fonc.2024.1435516

820 views

Original Research

Published on 12 Jul 2024

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

in Pharmacology of Anti-Cancer Drugs

Yunlong Wang
Xuan Deng
Qinggui Qiu
Mengchao Wan

Frontiers in Oncology

doi 10.3389/fonc.2024.1431023

1,000 views

Editorial

Published on 08 Jul 2024

Editorial: Precision therapy and biomarkers in head and neck squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Luis Abel Quiñones
Fujun Han
Ye Guo

Frontiers in Oncology

doi 10.3389/fonc.2024.1442630

605 views

Original Research

Published on 04 Jul 2024

Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml

in Pharmacology of Anti-Cancer Drugs

Lei Ren
Yanling Chen
Zixiong Liu
Guankai Huang
Weifeng Wang
Xu Yang
Baohua Bai
Yan Guo
Jian Ling
Xiaopeng Mao

Frontiers in Oncology

doi 10.3389/fonc.2024.1413953

858 views

Original Research

Published on 01 Jul 2024

Identification of a basement membrane-related gene signature for predicting prognosis, immune infiltration, and drug sensitivity in colorectal cancer

in Pharmacology of Anti-Cancer Drugs

Xiang Shengxiao
Sun Xinxin
Zhu Yunxiang
Tang Zhijie
Tang Xiaofei

Frontiers in Oncology

doi 10.3389/fonc.2024.1428176

1,249 views
1 citation

Mini Review

Published on 24 Jun 2024

EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring

in Pharmacology of Anti-Cancer Drugs

Yunlong Wang
Qinggui Qiu
Xuan Deng
Mengchao Wan

Frontiers in Oncology

doi 10.3389/fonc.2024.1426796

1,270 views

Perspective

Published on 21 Jun 2024

Elemental biomapping of human tissues suggests toxic metals such as mercury play a role in the pathogenesis of cancer

in Pharmacology of Anti-Cancer Drugs

Roger Pamphlett
David P. Bishop

Frontiers in Oncology

doi 10.3389/fonc.2024.1420451

1,167 views

Review

Published on 18 Jun 2024

Integrating Chinese medicine into mainstream cancer therapies: a promising future

in Pharmacology of Anti-Cancer Drugs

Baoyi Ni
Kaiyuan Xue
Jia Wang
Jilai Zhou
Lankang Wang
Xinmiao Wang
Ting Liu
Naijing Ye
Jiakang Jiang

Frontiers in Oncology

doi 10.3389/fonc.2024.1412370

1,651 views

Original Research

Published on 17 Jun 2024

Combined aqupla, paclitaxel liposome, and docetaxel treatment: survival and biomarker outcomes in recurrent ovarian cancer patients

in Pharmacology of Anti-Cancer Drugs

Jie Yang
Mengyu Zhang
Yilei Zhang
Lanfen Zhu
Qiming Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1422117

686 views

Original Research

Published on 13 Jun 2024

Transcriptomic convergence despite genomic divergence drive field cancerization in synchronous squamous tumors

in Pharmacology of Anti-Cancer Drugs

Qiu Xuan Tan
Nicholas B. Shannon
Weng Khong Lim
Jing Xian Teo
Daniel R. Y. Yap
Sze Min Lek
Joey W. S. Tan
Shih Jia J. Tan
Josephine Hendrikson
Ying Liu

Frontiers in Oncology

doi 10.3389/fonc.2024.1272432

811 views

Correction

Published on 03 Jun 2024

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

in Pharmacology of Anti-Cancer Drugs

Ningning Yan
Sanxing Guo
Siyuan Huang
Huixian Zhang
Xingya Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1412472

641 views

Methods

Published on 31 May 2024

ReCorDE: a framework for identifying drug classes targeting shared vulnerabilities with applications to synergistic drug discovery

in Pharmacology of Anti-Cancer Drugs

August J. John
Emily T. Ghose
Huanyao Gao
Meagan Luck
Dabin Jeong
Krishna R. Kalari
Liewei Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1343091

988 views

Navigation group

Articles

A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review

Retraction: Disulfiram chelated with copper inhibits the growth of gastric cancer cells by modulating stress response and Wnt/β-catenin signaling

Editorial: Immune-checkpoint inhibitors in anti-cancer armamentarium: a double-edged sword in risk of developing autoimmunity and immune-related adverse effects

Progress of natural sesquiterpenoids in the treatment of hepatocellular carcinoma

Withametelin inhibits TGF-β induced Epithelial-to-Mesenchymal Transition and Programmed-Death Ligand-1 expression in vitro

Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer

Editorial: Precision therapy and biomarkers in head and neck squamous cell carcinoma

Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml

Identification of a basement membrane-related gene signature for predicting prognosis, immune infiltration, and drug sensitivity in colorectal cancer

EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring

Elemental biomapping of human tissues suggests toxic metals such as mercury play a role in the pathogenesis of cancer

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Combined aqupla, paclitaxel liposome, and docetaxel treatment: survival and biomarker outcomes in recurrent ovarian cancer patients

Transcriptomic convergence despite genomic divergence drive field cancerization in synchronous squamous tumors

Corrigendum: The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

ReCorDE: a framework for identifying drug classes targeting shared vulnerabilities with applications to synergistic drug discovery